Insmed Incorporated (INSM)
Nasdaq · Bridgewater, New Jersey, USA · Founded 1988 · CEO Will Lewis
Valuation summary
$114.11 fair value versus $144.46 in the market, a difference of -21.0%. Rated Reduce.
| Fair value per share | $114.11 |
| Current share price | $144.46 |
| Upside / downside | -21.0% |
| Bear case | $76.68 |
| Bull case | $164.29 |
| Discount rate (WACC) | 10.4% |
| Terminal growth | 3.00% |
| Market capitalisation | $32B |
| EV / Sales | 21.2x |
About Insmed Incorporated
Will Lewis has been chief executive since 2012. Insmed develops medicines for serious lung diseases. Its first product, Arikayce, treats a hard-to-cure lung infection. In August 2025 US regulators approved Brinsupri, the first medicine for bronchiectasis, a chronic condition in which damaged airways cause repeated infections and which affects several hundred thousand Americans. The launch has been one of the fastest in recent years, and a third medicine for high blood pressure in the lungs is in late-stage trials.
Investment case
- Brinsupri is the only approved treatment for a common, long-neglected disease.
- The same drug is being tested in other inflammatory conditions.
- A late-stage pipeline beyond its two products.
Key risks
- Still loss-making while it funds a large launch.
- Other companies are developing drugs of the same type.
- Recent trial setbacks in new uses show the risk in the pipeline.
Revenue by segment
| Brinsupri | 60% |
| Arikayce | 40% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $2.4B | $-0.5B |
| Year 2 | $3.8B | $-0.3B |
| Year 3 | $5.3B | $0.2B |
| Year 4 | $6.8B | $0.9B |
| Year 5 | $8.1B | $2.0B |
What the street says
Seen as one of the most important new drug launches in biotech.
Comparable companies: MRNA · TEM · ALNY · NTRA · HUM · CNC · CAH · DXCM
Open the interactive model, price chart and sensitivity grid →